Give you a statement and table with its title in Markdown format, please determine whether the statement is supported or refuted by, or is unrelated to the table. It'a binary classification problem, you should choose the answer between supported and refuted. Table cells in one row are seperated by '|', and different rows are seperated by '
'.

Table:
| clinical status | compound name | trademark | marine organism α | chemical class | molecular target | clinical trials β | disease area |
| fda - approved | cytarabine (ara - c) | cytosar - u ® | sponge | nucleoside | dna polymerase | >50 / 711 | cancer |
| fda - approved | vidarabine (ara - a) | vira - a ® | sponge | nucleoside | viral dna polymerase | 0 | antiviral |
| fda - approved | ziconotide | prialt ® | cone snail | peptide | n - type ca 2 + channel | 2 / 5 | analgesic |
| fda - approved | eribulin mesylate (e7389) | halaven ® | sponge | macrolide | s microtubule | 19 / 27 | cancer |
| fda - approved | omega - 3 - fatty acid ethyl esters | lovaza ® | fish | omega - 3 fatty acids | triglyceride - synthesizing enzymes | 45 / 94 | hypertriglyceridemia |
| fda - approved | trabectedin (et - 743) eu approved only | yondelis ® | tunicate | alkaloid | minor groove of dna | 17 / 34 | cancer |
| phase iii | brentuximab vedotin (sgn - 35) | adcetris ® | mollusk | antibody - drug conjugate (mm auristatin e) | cd30 and microtubules | 9 / 19 | cancer |
| phase iii | plitidepsin | aplidin ® | tunicate | depsipeptide | rac1 and jnk activation | 1 / 7 | cancer |
| phase ii | dmxba (gts - 21) | n / a | worm | alkaloid | alpha - 7 nicotinic acetylcholine receptor | 0 / 3 | congnition , schizophrenia |
| phase ii | plinabulin (npi 2358) | n / a | fungus | diketopiperazine | microtubules and jnk stress protein | 1 / 2 | cancer |
| phase ii | elisidepsin | irvalec ® | mollusk | depsipeptide | plasma membrane fluidity | 1 / 2 | cancer |
| phase ii | pm00104 | zalypsis ® | nudibranch | alkaloid | dna - binding | 2 / 3 | cancer |
| phase ii | glembatumumab vedotin (cdx - 011) | n / a | mollusk | antibody drug conjugate (mm auristatin e) | glycoprotein nmb and microtubules | 1 / 3 | cancer |
| phase i | marizomib (salinosporamide a) | n / a | bacterium | beta - lactone - gamma lactam | 20s proteasome | 4 / 4 | cancer |
| phase i | pm01183 | n / a | tunicate | alkaloid | minor groove of dna | n / a | cancer |
| phase i | sgn - 75 | n / a | mollusk | antibody drug conjugate (mm auristatin f) | cd70 and microtubules | 2 / 2 | cancer |
| phase i | asg - 5 me | n / a | mollusk | antibody drug conjugate (mm auristatin e) | asg - 5 and microtubules | 2 / 2 | cancer |
| phase i | hemiasterlin (e7974) | n / a | sponge | tripeptide | microtubules | 0 / 3 | cancer |
| phase i | bryostatin 1 | n / a | bryozoa | polyketide | protein kinase c | 0 / 38 | cancer , alzheimers |
Title:
marine pharmacognosy
Statement:
the chemical pm00104 wih the trademark zalypsis ® is listed under the molecular target : dna - binding
Answer:
supported